Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1001 (LINC01001)
- Target
- LINC01001
- Molecular classification
- Long non-coding RNA (lncRNA), Intergenic non-coding RNA (lincRNA)
01
Overview
Long intergenic non-protein coding RNA 1001 (LINC01001) is a long non-coding RNA (lncRNA) transcript that does not overlap with protein-coding regions of the genome[1][5]. It acts mainly as a regulatory molecule, participating in the regulation of gene expression, cell proliferation, apoptosis, and chemoresistance, especially in cancer contexts such as lung adenocarcinoma and crizotinib-resistant non-small cell lung cancer[2][4][6]. LINC01001 interacts with proteins such as IGF2BP2, modulating downstream targets like MYC, and its overexpression is associated with poor prognosis and increased drug resistance. While it is not a classic therapeutic target like a receptor or enzyme, it is emerging as a functionally significant RNA species involved in cancer biology and therapy resistance[2][4].
- Other names
- LINC01001Long intergenic non-coding RNA 1001
02
Mechanism of action
Regulatory RNA: modulates crizotinib resistance by influencing the IGF2BP2/MYC axis, affecting tumor cell proliferation and apoptosis
03
Biological functions
Regulation of gene expressionCell proliferationApoptosisChemoresistance modulation
04
Disease associations
Cancer (lung adenocarcinoma, non-small cell lung cancer)Crizotinib-resistant non-small cell lung cancerMyeloma, multipleDressler's syndrome
05
Interacting drugs
Crizotinib (indirectly, through its role in mediating resistance)
06
Biomarkers
Biomarker for poor prognosis in lung adenocarcinoma and crizotinib-resistant NSCLC
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 1001 (LINC01001).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1001 (LINC01001).